Potential new pain killer drug developed by scientists at Leicester and Italy

Mar 16, 2007

A potential new pain-killing drug developed by medical scientists at the University of Leicester and Ferrara in Italy is to be discussed at a public lecture on 20th March.

Professor David Lambert, who has been involved in the development the drug in collaboration with Dr Girolamo Calo in Ferrara Italy, believes the new drug – called UFP-101 - avoids many of the side effects of morphine, currently the ‘gold standard’ in pain reduction.

He said: "In a 2005 survey for the British Pain Society 975 people were questioned about pain. Twenty one percent experienced pain every day or most days equating to ~10million across the whole UK.

"Morphine produces its clinical effects by interaction with opioid receptors. In addition to acting as a pain killer this drug produces a number of unwanted side effects of importance from a clinical (e.g., depression of breathing, constipation and tolerance) and social (addiction) viewpoints.

"Clearly there is a place for new morphine like drugs without these side effects and the University of Leicester Anaesthesia Division has been at the forefront of such preclinical research."

Since appointment in 1991 as a lecturer Professor Lambert has been working on opioids and opioid receptors with particular emphasis on understanding receptor function and the design and evaluation of new drugs to target these receptors.

In collaboration with Dr Girolamo Calo his laboratory has characterised a prototype analgesic (pain killer), acting at a new opioid receptor, with a much reduced side effect profile.

In his inaugural lecture he will describe the current place of opioids in the clinic and development of UFP-101.

Source: University of Leicester

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

New drugs to relieve cancer pain

Jun 21, 2010

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0